PDGFR

Platelet-derived growth factor receptors (PDGF-R) are cell surface tyrosine kinase receptors for members of the platelet-derived growth factor (PDGF) family. PDGF subunits -A and -B are important factors regulating cell proliferation, cellular differentiation, cell growth, development and many diseases including cancer. There are two forms of the PDGF-R, alpha and beta each encoded by a different gene. Depending on which growth factor is bound, PDGF-R homo- or heterodimerizes.

Cat. No.	Product name	CAS No.	Purity
T8541	Lenvatinib mesylate	857890-39-2	99.79%
T8541	Lenvatinib mesylate is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
T0520	Lenvatinib	417716-92-8	99.8000%
T0520	Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.
T0093	Sorafenib tosylate	475207-59-1	99.81%
T0093	Sorafenib is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
T7861	Flumatinib mesylate	895519-91-2	99.82%
T7861	Flumatinib mesylate is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.
T1895	SKLB 610	1125780-41-7	99.83%
T1895	SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2, and PDGFR at a rate of 97%, 65%, and 55%, respectively, a...
T6920	ON123300	1357470-29-1	99.84%
T6920	ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
T0097L	Pazopanib	444731-52-6	99.84%
T0097L	Pazopanib, a small molecule inhibitor, inhibits multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits VEGFR-1,...
T1792	Regorafenib	755037-03-7	99.87%
T1792	Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).
T60110	KN1022	205255-11-4	99.88%
T60110	KN1022 is an inhibitor of phosphorylation of platelet-derived growth factor (PDGF) receptor with IC50 of 0.26 μM.
T0093L	Sorafenib	284461-73-0	99.89%
T0093L	Sorafenib is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-4/B-Raf).
T2446	KI8751	228559-41-9	99.9%
T2446	KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
T2609	Masitinib	790299-79-5	99.91%
T2609	Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has ...
T1777	Nintedanib	656247-17-5	99.92%
T1777	Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).
T8544	Masitinib mesylate	1048007-93-7	99.92%
T8544	Masitinib mesylate is a selective and orally bioavailable c-Kit inhibitor (IC50 of 200 nM,540/800 nM,510 nM for human recombinant c-Kit;PDGFRα/β;LynB,respectivel...
T6230	Imatinib	152459-95-5	99.94%
T6230	matinib is an inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit (IC50: 600/100/100 nM).
T2500	Cediranib	288383-20-0	99.94%
T2500	Cediranib (AZD2171) is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro, also inhibits Flt1/4 (IC50: 5 nM/...
T4320	Flumatinib	895519-90-1	99.95%
T4320	Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
T0080	Trapidil	15421-84-8	99.96%
T0080	Trapidil is a coronary vasodilator agent. It was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic ...
T5001	Nintedanib esylate	656247-18-6	99.96%
T5001	BIBF 1120 esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β
TN2354	Methylnissolin	73340-41-7	99.98%
TN2354	3-Hydroxy-9,10-dimethoxyptercarpan is derived from Astragalus and has antibacterial and anti-cancer effects.